Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, tolerability and mechanism of action of boswellic acids in multiple sclerosis and clinically isolated syndrome
2009-014724-32Phase 2Completed
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Oct 2010
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of boswellia serrata in multiple sclerosis (MS) and clinically isolated syndrome (CIS), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Number and volume of total gadolinium-enhancing lesions. Started Oct 2010; status: completed.
02
Drugs
boswellia serrata
03
Conditions
multiple sclerosis (MS)clinically isolated syndrome (CIS)
Beyond the preview
Go deeper on 2009-014724-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014724-32.